Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.52 |
| ▸ | STS | P08842 | 1/20 | 0.46 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29497188 | 1.00 | GRM5 (0.52) | GRM5STSALDH2CYP3A4TP53 | |
| SCHEMBL22530217 | 0.81 | STS (0.46) | STSALDH2MAPTPOLBGPR119 | |
| SCHEMBL25260635 | 0.81 | NOTUM (0.42) | GRM5CYP3A4MEN1KMT2A | |
| SCHEMBL21722989 | 0.78 | STS (0.43) | STSALDH2MAPTPOLBGPR119 | |
| SCHEMBL14088779 | 0.78 | GRM5 (0.47) | GRM5STSTP53MAPTRXFP1 | |
| SCHEMBL23883197 | 0.77 | GRM5 (0.51) | GRM5STSCYP3A4MAPTPOLB | |
| SCHEMBL5119545 | 0.77 | GRM5 (0.52) | GRM5STSCYP3A4USP30MEN1 | |
| SCHEMBL23777806 | 0.77 | STS (0.48) | STSTP53MAPTPOLBRXFP1 | |
| SCHEMBL20757065 | 0.76 | TP53 (0.52) | STSTP53MAPTPOLBRXFP1 | |
| SCHEMBL5710832 | 0.76 | GRM5 (0.52) | GRM5STSCYP3A4TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | CBR3, BRIX1, CCNY | GRM5 3679/4885STS 1021/4885ALDH2 2918/4885 |
| US-11981661-B2 | Heterocyclic compounds | CBR3, BRIX1, CCNY | GRM5 3679/4885STS 1021/4885ALDH2 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.